444 related articles for article (PubMed ID: 33059241)
1. Non-small cell lung carcinomas with a minor sarcomatoid component and pleomorphic carcinomas are associated with high expression of programmed death ligand 1.
Tancoš V; Farkašová A; Kviatkovská Z; Grendár M; Líšková A; Huťka Z; Plank L
Pathol Res Pract; 2020 Dec; 216(12):153238. PubMed ID: 33059241
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 Expression in Non-Small-Cell Lung Cancer Including Various Adenocarcinoma Subtypes.
Miyazawa T; Marushima H; Saji H; Kojima K; Hoshikawa M; Takagi M; Nakamura H
Ann Thorac Cardiovasc Surg; 2019 Feb; 25(1):1-9. PubMed ID: 30282880
[TBL] [Abstract][Full Text] [Related]
3. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
[TBL] [Abstract][Full Text] [Related]
4. Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.
Sepesi B; Cuentas EP; Canales JR; Behrens C; Correa AM; Vaporciyan A; Weissferdt A; Kalhor N; Moran C; Swisher S; Wistuba I
Semin Thorac Cardiovasc Surg; 2017 Autumn; 29(3):408-415. PubMed ID: 29195578
[TBL] [Abstract][Full Text] [Related]
5. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
[TBL] [Abstract][Full Text] [Related]
6. [Protein expression of PD-L1 and clinico-pathological data in a cohort of 53 patients with resectable non small cell lung cancer (NSCLC). Concordance between clones (22C3 and 28-8) and observers. Correlation and prognostic value of clinico-pathological data].
Esteban-Rodríguez I; Ruiz Bravo-Burguillos E; Rosas R; Losantos I; Rodríguez-Antolín C; de Castro J
Rev Esp Patol; 2020; 53(1):10-18. PubMed ID: 31932004
[TBL] [Abstract][Full Text] [Related]
7. Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas.
Ng Kee Kwong F; Laggner U; McKinney O; Croud J; Rice A; Nicholson AG
Histopathology; 2018 May; 72(6):1024-1032. PubMed ID: 29323731
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.
Rashed HE; Abdelrahman AE; Abdelgawad M; Balata S; Shabrawy ME
Turk Patoloji Derg; 2017; 1(1):211-222. PubMed ID: 28832075
[TBL] [Abstract][Full Text] [Related]
9. Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay.
Scorer P; Scott M; Lawson N; Ratcliffe MJ; Barker C; Rebelatto MC; Walker J
Diagn Pathol; 2018 Jul; 13(1):47. PubMed ID: 30041679
[TBL] [Abstract][Full Text] [Related]
10. Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer.
Yu H; Brustugun OT; Ekman S; Botling J; La Fleur L; Micke P; Solberg S; Berglund A; Rivard C; Hirsch FR
Clin Lung Cancer; 2021 Jul; 22(4):e555-e562. PubMed ID: 33214079
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of the tumor immune microenvironment in pulmonary pleomorphic carcinoma.
Amemiya R; Miyoshi T; Aokage K; Suzuki J; Hoshino H; Udagawa H; Tane K; Sugano M; Kojima M; Fujii S; Kuwata T; Ochiai A; Goto K; Ikeda N; Tsuboi M; Ishii G
Lung Cancer; 2021 Mar; 153():56-65. PubMed ID: 33454518
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological analysis of programmed death-ligand 1 testing in tumor cells of 325 patients with non-small cell lung cancer: Its predictive and potential prognostic value.
Farkašová A; Tancoš V; Kviatkovská Z; Huťka Z; Mičák J; Scheerová K; Szépe P; Plank L
Cesk Patol; 2018; 54(3):137-142. PubMed ID: 30445818
[TBL] [Abstract][Full Text] [Related]
13. Programmed death ligand-1 expression levels, clinicopathologic features, and survival in surgically resected sarcomatoid lung carcinoma.
Ağaçkıran Y; Aksu F; Akyürek N; Ercan C; Demiröz M; Aksu K
Asia Pac J Clin Oncol; 2021 Jun; 17(3):280-288. PubMed ID: 32929886
[TBL] [Abstract][Full Text] [Related]
14. Programmed death ligand-1 expression and its association with the degree of differentiation and the presence of necrosis in non-small cell lung carcinoma.
Blichárová A; Tancoš V; Benetinová Z; Verbóová Ľ; Grendár M; Mazuráková A; Plank L; Mechírová E
Pathol Res Pract; 2023 Feb; 242():154296. PubMed ID: 36610327
[TBL] [Abstract][Full Text] [Related]
15. Programmed cell death ligand 1 expression in cytologic and surgical non-small cell lung carcinoma specimens from a single institution: Association with clinicopathologic features and molecular alterations.
Mei P; Shilo K; Wei L; Shen R; Tonkovich D; Li Z
Cancer Cytopathol; 2019 Jul; 127(7):447-457. PubMed ID: 31025831
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study.
Chen YB; Mu CY; Huang JA
Tumori; 2012 Nov; 98(6):751-5. PubMed ID: 23389362
[TBL] [Abstract][Full Text] [Related]
17. Programmed death-1 ligand 1 and 2 are highly expressed in pleomorphic carcinomas of the lung: Comparison of sarcomatous and carcinomatous areas.
Kim S; Kim MY; Koh J; Go H; Lee DS; Jeon YK; Chung DH
Eur J Cancer; 2015 Nov; 51(17):2698-707. PubMed ID: 26329973
[TBL] [Abstract][Full Text] [Related]
18. Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas.
Driver BR; Miller RA; Miller T; Deavers M; Gorman B; Mody D; Ge Y; Barrios R; Bernicker E; Kim M; Cagle PT
Arch Pathol Lab Med; 2017 Nov; 141(11):1529-1532. PubMed ID: 28829153
[TBL] [Abstract][Full Text] [Related]
19. Programmed death-ligand 1 expression on direct Pap-stained cytology smears from non-small cell lung cancer: Comparison with cell blocks and surgical resection specimens.
Lozano MD; Abengozar-Muela M; Echeveste JI; Subtil JC; Bertó J; Gúrpide A; Calvo A; de Andrea CE
Cancer Cytopathol; 2019 Jul; 127(7):470-480. PubMed ID: 31245924
[TBL] [Abstract][Full Text] [Related]
20. Spindle cell and pleomorphic ("sarcomatoid") carcinomas of the lung: an immunohistochemical analysis of 86 cases.
Weissferdt A; Kalhor N; Rodriguez Canales J; Fujimoto J; Wistuba II; Moran CA
Hum Pathol; 2017 Jan; 59():1-9. PubMed ID: 27569293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]